Skip to main content

News categories: Publication

New insights into our immune system

Bcl6 important for the formation of certain dendritic cells.

Dendritic cells play an important role in setting the course of our immune system. However, what determines their heterogeneity and functional specialization is still not sufficiently understood. An international collaboration consisting of researchers from the University Hospital Bonn (UKB), the University of Bonn and the Technical University of Denmark, among others, has investigated the role of the transcription factor Bcl6 in dendritic cells in a mouse model and discovered that a subgroup is highly dependent on this protein. The findings contribute to a better understanding of immunological processes during infections, vaccinations, allergies and autoimmunity. The results have now been published in the renowned scientific journal "Nature Communications".

Dendritic cells are part of our innate immune system and occupy a central position there. "These cells are particularly good at initiating an effective T-cell-mediated immune response of the acquired immune system," explains co-corresponding author Prof. Dirk Baumjohann from the Medical Clinic III for Hematology, Oncology, Immuno-Oncology and Rheumatology at the UKB, who is a member of the Cluster of Excellence ImmunoSensation2 and the Transdisciplinary Research Area (TRA) "Life & Health" at the University of Bonn. "However, it is still unclear what exactly drives their heterogeneity and functional specialization."

Previous studies have investigated the function of the protein Bcl6 in dendritic cells - in some cases with varying results. The aim of the current study is to harmonize the sometimes contradictory data using an in-depth analysis.

Bcl6 as an important transcription factor

The researchers therefore used a mouse model to investigate how the absence of Bcl6 affects all dendritic cell subgroups. "We found that in particular one specific dendritic cell subgroup (cDC2) is highly dependent on Bcl6," explains Prof. Katharina Lahl, who led the project at the Technical University of Denmark and is now continuing her work in Calgary. "Bcl6 deficiency leads to a lack of a dendritic cell subpopulation and results in impaired antibody responses in the spleen." As a result, the animals showed weakened immune responses in infection and vaccination models. "Bcl6 deficiency also led to the loss of the cDC2 subgroup in the large intestine, which caused a delayed recovery from an intestinal infection," adds Prof. Lahl.

In addition, the researchers were able to demonstrate with their study that the gene expression program in dendritic cells is already decisive for the subsequent cell fate of T cells and the associated immune response.

"The function of Bcl6 in dendritic cells overlaps with the already known function of Bcl6 in T cells and B cells and thus complements a gene expression program that acts synergistically across different immune cells," says Prof. Baumjohann. "These findings can contribute to the development of new therapeutic strategies, for example by strengthening specific dendritic cells during infection or vaccination or weakening them in allergies and autoimmune diseases."

Publication:

Hongkui Xiao, et al (2024)

Genomic deletion of Bcl6 differentially affects conventional dendritic cell subsets and compromises Tfh/Tfr/Th17 cell responses

Nature Communications, DOI: https://doi.org/10.1038/s41467-024-46966-6

Contact:

Prof. Dirk Baumjohann

Medical Clinic III for Haematology, Oncology, Immuno-oncology and Rheumatology

University Hospital Bonn

Cluster of Excellence ImmunoSensation2 & TRA "Life & Health", University of Bonn

E-mail: dirk.baumjohann@uni-bonn.de

Press release of the University of Bonn

Contact:

Johannes Seiler

Science editor

University of Bonn

E-Mail: j.seiler@uni-bonn.de

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview